Engrail Therapeutics, a San Diego, CA-based precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, raised $157M in Series B funding.
The round was led by F-Prime Capital, Forbion, and Norwest Venture Partners, with participation from RiverVest Venture Partners, Red Tree Venture Capital, funds managed by abrdn Inc., Ysios Capital, Longwood Fund, Eight Roads Ventures, and existing founding investor Pivotal Life Sciences.
The company intends to use the funds for the advancement of its pipeline through multiple stages of clinical development.
Led by Vikram Sudarsan, Ph.D., president and CEO, Engrail is a clinical-stage pharmaceutical company whose purpose is to deliver transformational therapies that improve the lives of patients with diseases with significant unmet medical need including anxiety disorders, depression, posttraumatic stress disorder, and rare neurodegenerative diseases.
Following this financing, Stacie Weninger, Ph.D. (F-Prime), Jasper Bos, Ph.D. (Forbion), Tiba Aynechi, Ph.D. (Norwest), Niall O’Donnell, Ph.D. (RiverVest), and Heath Lukatch, Ph.D. (Red Tree) have joined the Engrail board of directors.
